Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114230 · ClinicalTrials.gov registry record · Phase 1
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer
A Phase 1 study of Renal Cell Carcinoma and Pharmacokinetics of AGS-16M8F, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT01114230 is a Phase 1 study of Renal Cell Carcinoma and Pharmacokinetics of AGS-16M8F that has completed, run by Astellas Pharma. The registered enrollment target is 26 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01114230, a Phase 1 study of Renal Cell Carcinoma and Pharmacokinetics of AGS-16M8F, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this dose escalation study is to examine the safety and pharmacokinetics (PK) of AGS-16M8F administered in subjects with advanced renal cell carcinoma.
Conditions Studied
Interventions
- DRUG AGS-16M8F
Study Locations (3)
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01114230
The ClinicalTrials.gov registry entry for NCT01114230 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (89% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which AGS-16M8F is the first listed.
NCT01114230 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, New York, Washington.
Frequently Asked Questions
What is clinical trial NCT01114230 about?
NCT01114230 is a clinical study titled "A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer". The purpose of this dose escalation study is to examine the safety and pharmacokinetics (PK) of AGS-16M8F administered in subjects with advanced renal cell carcinoma.
What is the current status of trial NCT01114230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2010-08. Estimated completion is 2012-11.
What conditions does trial NCT01114230 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Pharmacokinetics of AGS-16M8F.
What interventions are being tested in trial NCT01114230?
The interventions under investigation include: AGS-16M8F (DRUG).
Who is sponsoring clinical trial NCT01114230?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01114230 being conducted?
This trial has 3 study locations across Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.